Drugmakers Dodge Another Bullet in Trump's Drug Pricing Report
- Report blames high prices on foreign governments, regulation
- Calls for ‘preserving incentives’ for private innovation
This article is for subscribers only.
A White House report on drug pricing is another sign pharmaceutical companies can rest easy: President Donald Trump won’t act on past threats to take drastic measures to lower prices.
The 30-page report circulated by the president’s Council of Economic Advisers blames high drug prices on foreign governments, as well as U.S. regulations, hospitals, middlemen known as pharmacy-benefit managers and high costs of innovation -- basically everyone but the drugmakers themselves. Bottom line: Big drugmakers are dodging another bullet in the finger-pointing game.